Nanovery Gains Momentum with New Investment for RNA Therapeutics

Northstar Ventures has provided significant backing to Nanovery, a Newcastle-based company, with a £1.1 million investment sourced from both the North East Innovation Fund and Northstar EIS Growth Fund. This funding, complemented by contributions from fellow investors Smartlink and a grant from Innovate UK's investor partnership program, is intended to bolster Nanovery's development of a new class of drugs known as RNA therapeutics. These therapeutics show promise in addressing previously untreatable diseases, with enormous market potential predicted to exceed $20 billion by 2030. While RNA therapies present benefits such as swift drug development with fewer side effects, challenges remain in molecule stability and targeted delivery. Nanovery's platform overcomes these hurdles with a system that enables low-concentration testing through straightforward processes using standard lab equipment, potentially positioning it as a leader in bioanalysis solutions for RNA drugs. The company has already secured R&D deals with notable pharma companies, highlighting its robust potential for commercial success. Investment by Northstar Ventures, known for funding high-growth businesses addressing critical societal issues, further underscores confidence in Nanovery's impact and innovative solutions in synthetic biology.